PD1 Resistant Head and Neck Cancer Market is projected to reach US$ 5 billion by 2033

The advancements in non-surgical procedures and therapies such as immunotherapy and targeted therapy are supporting the adoption rate of PD1-resistant head and neck cancer drugs among patients across the globe.

In 2023, the Global PD1 Resistant Head And Neck Cancer Market Size is projected to reach a value of US$ 1.54 billion and is anticipated to reach US$ 5 billion by 2033, exhibiting a CAGR of 12.5%. The increasing geriatric population and initiatives by government and non-governmental organizations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer (SPOHNC) are contributing to the favorable growth environment for this market.

Immunotherapy is an innovative cancer treatment method that can be used to treat various types of cancers, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. While some tumors respond well to traditional chemotherapy, in other cases, immunotherapy is combined with conventional cancer treatments to boost the body's natural defenses against cancer. The immune system functions by detecting and eliminating abnormal cells, thereby preventing or hindering the development of various malignancies. Immune cells are sometimes found in and around tumors. The consumption of alcohol and cigarettes accounts for an estimated 75% of head and neck cancers.

A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16237

However, standard head and neck cancer treatments frequently involve a combination of radiation and chemotherapy, which can cause several adverse effects such as hair loss, speech difficulties, and the loss of the natural voice. After undergoing cancer surgery, patients may also experience difficulty eating. These factors are likely to restrict market growth.

Key Takeaways

• North America is expected to dominate the Head and Neck cancer market with a CAGR of 11.1% during the forecast period.
• APAC is projected to grow with a fastest CAGR of 11.5% during the forecast period.
• PDL1 Inhibitors is anticipated to lead the market by product type.
• Advancements in biochemistry and Genomics like Immunotherapy will lead to market expansion.
• North America is projected to dominate PDL1 segment market by 2033.
• In APAC, China will dominate the market with market value of USD 250 Million in 2023.

“With rapid advancements in oncology, healthcare practitioners are discovering novel approaches to diagnose and treat the most debilitating cancers, including PD1 resistant HNC. This is paving way for various avenues for developing treatment approaches,” remarks an FMI analyst.

For any queries linked with the report, ask an analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16237

Competitive Landscape

Key players in the Head and Neck Cancer market are: Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.

• In February 2020, Galera Therapeutics, Inc., announced that Avasopasem manganese (GC4419), a novel drug molecule is in their pipeline. Avasopasem manganese (GC4419), the candidate drug molecule is being developed for reducing the severe oral mucositis (SOD) which is normally induced due to radiotherapy. Avasopasem manganese (GC4419) selectively and rapidly convert superoxide into hydrogen peroxide and oxygen, which in turn protect the normal tissues from the ill-effects of superoxide. If the condition is left untreated, the superoxide can attack and damage the non-cancerous tissue, leading to many side-effects, which can limit the efficiency of radiotherapy in the patients.
• In July 2022, Bristol Myers Squibb received positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending approval for LAG-3-blocking antibody combination Opdualag (nivolumab and relatlimab) for the treatment of patients with unresectable or metastatic melanoma.
• In October 2021, Merck received the United States Food and Drug Administration (FDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test.

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16237

Key Segments Profiled in the PD1 Resistant Head and Neck Cancer Market Industry Survey

PD1 Resistant Head and Neck Cancer Market by Product:

Cytotoxic Agents

• Antimetabolites
• Antitubulins
• Others - Platinum Agents, Fluoropyrimidines

EGFR Inhibitors

• Erbitux
• Vectibix
• Theracim/Theraloc

EGFR Inhibitors

• Tarceva
• Tykerb/Tyverb

PD1 Inhibitors

• Keytruda
• Opdivo

Pipeline Drugs

• EGFR Inhibitors
• PDL1 Inhibitors
• CTLA4 Inhibitors